EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Prevention of gram positive g positive bacteremia ba with low dose vancomycin va infusion






Pediatric Research 31(4 PART 2): 278A

Prevention of gram positive g positive bacteremia ba with low dose vancomycin va infusion



Accession: 032944115



Related references

Kacica, M.A.; Valentine, L.; Horgan, M.; Hanley, E.M.; Evans, A.; Kan, H.; Steele, L.M.; Venezia, R.A., 1996: Protocol for continuous low-dose Vancomycin infusion for prevention of gram-positive sepsis in neonates weighing less than 1500 grams. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 237

Chua, K.; Howden, B.P., 2010: Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. The role of vancomycin for treating serious methicillin-resistant Staphylococcus aureus infections and the optimal method of administration of anti-Gram-positive antibiotics have been recently questioned. This review summarizes the current literat...

Kacica M.A.; Horgan M.J.; Yocum D.; Ochoa L.; Lepow M.L.; Venezia R.A., 1992: Continuous infusions of low dose vancomycin va in neonates prevents gram positive bacteremia g plus ba without altering va susceptibilities. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 154

Deville, J.G.; Edge Padbury, B.; Naberhuis Stehouwer, S.; Bruss, J.B.; The Linezolid Pediatric Study Group, 2003: Linezolid vs vancomycin in children with resistant gram-positive bacteremia. Pediatric Research 53(4 Part 2): 322A, April

Schots, R.; Trullemans, F.; Van Riet, I.; Kaufman, L.; Hafsia, A.; Meddeb, B.; Bel Hadj Ali, Z.; Ben Abid, H.; Lauwers, S.; Van Camp, B., 1999: The clinical impact of early gram-positive bacteremia and the use of vancomycin after allo-BMT. Blood 94(10 SUPPL 1 PART 2): 372b, Nov 15

Teinturier, C.; Hartmann, O.; Lemerle, J.; Benhamou, E.; Maraninchi, D., 1995: Prevention of gram-positive infections in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomized controlled trial of vancomycin. Between January 1986 and June 1988, 155 patients (73 children and 82 adults), who were candidates for bone marrow transplantation, were included in a randomized controlled trial (75 patients in vancomycin group and 80 patients in the group without...

Espinoza, R.; Kusne, S.; Pasculle, A.W.; Wada, S.; Fung, J.; Rakela, J., 1997: Leuconostoc bacteremia after liver transplantation: another cause of vancomycin resistant gram-positive infection. Leuconostoc sp. are gram-positive bacteria intrinsically resistant to vancomycin, which can be confused with streptococci based on routine microbiological-characteristics. Infections secondary to Leuconostoc are uncommon, and usually affect patien...

Zimmermann, A.E.; Katona, B.G.; Plaisance, K.I., 1995: Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. We attempted to determine if an association exists between vancomycin serum concentrations resulting from traditional dosing regimens, and efficacy and toxicity outcomes. We reviewed the medical charts of 273 consecutive patients prescribed 273 co...

Borja, J.; Gratacós, L.; García-Barbal, J., 1994: Vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. Journal of Infectious Diseases 170(5): 1344-1345

Azuero, R.; Horgan, M.J.; Venezia, R.A.; Martha, L.L., 2002: Use of vancomycin for the prevention of gram positive sepsis in very low birth weight premature infants Update on development of vancomycin resistance. Pediatric Research 51(4 Part 2): 306A, April